Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
University of Southern California
Boehringer Ingelheim
West China Hospital
Incyte Corporation
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Seagen Inc.
Eli Lilly and Company
Janssen Research & Development, LLC
Pfizer
Janssen Research & Development, LLC
Novartis
Dana-Farber Cancer Institute
Exelixis
Pfizer
M.D. Anderson Cancer Center
Novartis
Tomsk National Research Medical Center of the Russian Academy of Sciences
Ohio State University Comprehensive Cancer Center
Kivu Bioscience Inc.
AstraZeneca
Alterome Therapeutics, Inc.
Eli Lilly and Company
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
AstraZeneca
M.D. Anderson Cancer Center
Boehringer Ingelheim
Hoffmann-La Roche
Cartography Biosciences
Roswell Park Cancer Institute
Coherus Oncology, Inc.
ViroMissile, Inc.
Eisai Inc.
Lyell Immunopharma, Inc.
Erasca, Inc.
Massachusetts General Hospital
Thomas Jefferson University
Fudan University
Pfizer